Author

C. Hurtz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:genetic perturbation / CRISPR· 2 Organism:human· 2 Research Focus:benchmarking· 1 Approach:biophysical modeling· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

H. Geng· 2 shared A. Kumar· 1 shared A. P. Wiita· 1 shared A. Vogt· 1 shared C. Hong· 1 shared C. W. Chen· 1 shared D. M. Weinstock· 1 shared E. Aghania· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

H. Geng

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Pharmacologic Inhibition of DYRK1A Results in MYC Hyperactivation and ERK Hyperphosphorylation rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition

C. Hurtz, V. S. S. A. Ayyadevara, G. Wertheim, J. Chukinas, J. P. Loftus, S. J. Lee, A. Kumar, R. S. Bhansali, S. Swaminathan, H. Geng, T. Milne, X. Hua, K. M. Bernt, T. Besson, J. Shi, , S. K. Tasian

This study shows that inhibiting DYRK1A in KMT2A-R ALL cells leads to MYC upregulation and ERK hyperphosphorylation, making them sensitive to BCL2 inhibition.

bioRxiv · Oct 2, 2022 · PreprintCancer Biology

Signaling input from divergent pathways subverts malignant B-cell transformation

L. N. Chan, M. A. Murakami, M. E. Robinson, R. Caeser, T. Sadras, J. Lee, K. N. Cosgun, K. Kume, V. Khairnar, G. Xiao, M. Ahmed, E. Aghania, G. Deb, C. Hurtz, S. Shojaee, , M. Muschen

This study shows that malignant B-cell transformation requires convergence on a single oncogenic pathway, while divergent pathways can subvert transformation and are targets for new therapeutic strategies.

bioRxiv · Mar 12, 2020Cancer Biology